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Methadone maintenance treatment (MMT) is widely 
recognized as an intervention for treating opioid depen-
dence (primarily heroin dependence). Researchers have 
described MMT in terms of its effectiveness for reducing 
heroin and/or other drug use (Fareed, Casarella, Amar, 
Vayalapalli, & Drexler, 2009; Simoens, Matheson, Bond, 
Inkster, & Ludbrook, 2005; Teesson et al., 2006), risk 
behaviors associated with HIV (Corsi, Lehman, & 
Booth, 2009; Gowing, Farrell, & Bornemann, 2008; Hartel 
& Schoenbaum, 1998), crime (Lind, Chen, Weatherburn, & 
Mattick, 2005; Sheerin, Green, Sellman, Adamson, & 
Deering, 2004), and fatal overdose involving heroin 
(Fugelstad, Stenbacka, Leifman, Nylander, & Thiblin, 2007).
Despite a vast research base into MMT, scholars have 
suggested that MMT outcome studies are limited because 
of methodological problems associated with program 
attrition, sample bias, and measures (Fischer, Rhem, 
Kim, & Kirst, 2005). For example, client retention in 
MMT is one outcome variable that has been used to gauge 
the effectiveness of MMT. Retention is deemed to be 
important because it reduces the likelihood of relapse into 
heroin use, and in turn, heroin overdose and injecting 
behaviors associated with blood-borne viruses. However, 
clients who have left treatment during the early stages of 
MMT are often excluded from retention studies (Fischer 
et al.). This omission can artificially boost the overall 
retention rate, i.e., making it appear higher than the true 
value had early program leavers been included in the cal-
culation. This form of sample selection bias is important, 
particularly because dropping out of MMT has tended to 
occur more frequently within the first few months of 
treatment (Farré, Mas, Torrens, Moreno, & Camí, 2002). 
In some studies, upwards of 40% to 60% of MMT clients 
were shown to leave treatment within 12 to 14 months 
(Kellogg et al., 2006; Liu et al., 2009; Nosyk, Marsh, 
Sun, Schecter, & Anis, 2010). In their review of the litera-
ture, Fischer et al. concluded that “patient retention . . . is 
the exception rather than the rule” (p. 3).
Compared to the large number of MMT outcome eval-
uation studies, less emphasis has been placed on MMT 
from the perspective of clients, although this line of 
inquiry is expanding. Scholars have identified important 
links between client satisfaction and retention in MMT 
(Villafranca, McKeller, Trafton, & Humphreys, 2006), 
and have linked client satisfaction at 3 and 12 months 
(Kelly, O’Grady, Brown, Mitchell, & Schwartz, 2010). 
Why do so many MMT clients leave treatment early, and 
what factors contribute to it? Although individual-level 
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factors have been found to be associated with MMT drop-
out (Mancino et al., 2010), many investigators have found 
that structural factors create the conditions for leaving 
MMT prematurely (Bao et al., 2009; Harris et al., 2006; 
Porter, 1999; Reisinger et al., 2009).
MMT clients have voiced concerns about daily collec-
tions of methadone (Holt, 2007), supervised consumption 
for stable clients (Stone & Fletcher, 2003), limited metha-
done collection times (Anstice, Strike, & Brands, 2009), 
lack of privacy in pharmacy settings (Anstice et al.; 
Fraser, Valentine, Treloar, & Macmillan, 2007; Matheson, 
1998; Stone & Fletcher), lengthy wait times for collec-
tions (Fraser & Valentine, 2008) and the control of meth-
adone over daily lifestyles (Reisinger et al., 2009). Dole 
and Nyswander (1980) highlighted structural and inter-
personal factors, and noted the importance of mutual 
respect between treatment staff and MMT clients. They 
suggested that, without this respect,
an adversary relationship develops between patients 
and staff, reinforced by arbitrary rules and the indif-
ference of persons in authority. Patients held in 
contempt by the staff continue to act like addicts. . . . 
Understandably, methadone maintenance programs 
today have little appeal to the communities or to the 
majority of heroin addicts on the street. (p. 261)
More than 30 years ago, Newman (1976) observed 
that the rigid structure of MMT programs deviated sub-
stantially from the way that MMT was originally envi-
sioned. In practice, MMT provision is highly regulated, 
characterized by intensive social control (Des Jarlais, 
Paone, Friedman, Peyser, & Newman, 1995), and yet still 
is considered to be a dominant modality for treating her-
oin dependence.
In this article, we link the theoretical concepts of 
social control and stigma to examine client experiences 
with MMT. We draw from the work of Cohen (1985), 
who described the societal shifts that incorporate the 
disciplining and regulating of deviance. He viewed 
social control as the “organized responses” to deviance 
(p. 3) that are deemed necessary to establish order, 
define moral boundaries, and monitor deviants in a pan-
optic world. Social control is fueled  by power imbal-
ances whereby those in positions of power can identify, 
track, control, and punish behavior; hence, power is a 
critical element of social control. The concept of power 
also features in stigma theory, because stigma derives 
from unequal power relations (Gilmore & Somerville, 
1994); thus, social control and stigma are inherently 
linked through the concept of power. Link and Phelan 
(2006, p. 528) suggested that stigma is best understood 
as a multistage social process that begins with human 
differences that are labeled and stereotyped. Labelers 
(those with power) impose “them/us” distinctions, and 
discrimination and loss of status are experienced by the 
individuals who are labeled (those without power). 
Once in place, stigma can spread and create additional 
power imbalances (Parker & Aggleton, 2003).
Stigma can be practiced by individuals, and within 
peer groups, communities, and agencies (Mill, Edwards, 
Jackson, MacLean, & Chaw-Kant, 2010; Yang et al., 
2007). In the fields of mental health and HIV/AIDS, 
scholars have found that stigma negatively affects treat-
ment entry, relationships with health care providers, 
and treatment retention (Link & Phelan, 2006; Varas-
Díaz, Serrano-García, & Toro-Alfonso, 2005). Drawing 
from the literature on mental illness, institutional stigma 
(macro level) is differentiated from internalized stigma 
(micro level). The former refers to the “rules, policies and 
procedures of private and public entities in positions of 
power that restrict the rights and opportunities of people 
with mental illness” (Livingston & Boyd, 2010, p. 2151). 
Institutional stigma creates the conditions for people to 
internalize the stigma they experience (Campbell & 
Deacon, 2006). In turn, “they believe they are devalued 
members of society” (Livingston & Boyd, p. 2151). Not 
all individuals will internalize the institutional stigma that 
they experience; internalized sigma occurs when indi-
viduals “accept the social meaning” of the stigma (Lloyd, 
2010, p. 43). In this article, we analyze data from four 
studies to explore how MMT clients experience the 
mechanisms of social control under MMT provision. We 
also examine the nature of institutionalized stigma in 
MMT delivery, and the ways in which this macro-level 
stigma reinforces spoiled identities. We link these issues 
to the prospects of recovery among MMT clients, and 
question whether the provision of MMT is consistent 
with the wider philosophy of contemporary treatment and 
harm reduction.
The Setting
The study sites included Northern Ireland (North) and the 
Republic of Ireland (South). The regions are divided by a 
land border, with separate governmental jurisdiction over 
health, education, social welfare, and other services. The 
availability of MMT provision in the North commenced 
in 2004, after several years of policy that proscribed any 
form of pharmacological-based maintenance for opioid 
dependence. Referrals to one of 13 specialist addiction 
treatment services are primarily made by a general prac-
titioner (GP). The substitute prescribing scheme (MMT 
or high-dose buprenorphine) operates within these spe-
cialized services and under the context of shared care.
On 31 March 2010, 466 individuals were being pre-
scribed methadone or high-dose buprenorphine in 
Northern Ireland (Department of Health, Social Services 
and Public Safety, 2010). Of this figure, 52% were in 
MMT in receipt of dosages that ranged from 5mg to 
 at Queens University on June 11, 2012qhr.sagepub.comDownloaded from 
812  Qualitative Health Research 22(6)
160mg per day (mean dosage = 66.6mg per day). 
Mechanisms of surveillance include the Addicts Index 
and the Northern Ireland Drugs Misuse Database 
(DMD). The Addicts Index is updated annually, and 
includes the names of individuals who have been offi-
cially identified as “addicts” by GPs and other health 
professionals, who are required by law to report patients 
whom they believe or reasonably suspect to be addicted 
to one of several opioids or cocaine. This information is 
supplied in writing to the Chief Medical Officer. These 
data also include patients who are referred to special-
ized addiction services; thus, MMT clients are included 
in the Addicts Index. The DMD includes information 
provided by statutory and voluntary agencies, and 
reflects individuals presenting for drug treatment. One 
major difference between the two surveillance systems 
is that individuals presenting for treatment are required 
to provide consent before their details can be included in 
the DMD database.
MMT has been officially available in the South of 
Ireland (largely Dublin) since 1992, although several 
changes in its provision have been implemented since 
then. The Methadone Treatment Protocol was imple-
mented in 1998 and encompassed systematic procedures 
for prescribing methadone and for managing patients in 
receipt of methadone treatment (Butler, 2002). The 
Protocol sought to expand the number of people in meth-
adone maintenance by encouraging community-based 
treatment in the context of primary care. General practi-
tioners are required to complete at least one course of 
training (minimum 3 hours) if they intend to prescribe 
methadone. The level of addiction training and experi-
ence with treating MMT clients are the main factors that 
determine MMT caseload within primary care settings. A 
total of 259 GPs worked with the Methadone Treatment 
Protocol in 2008 (Health Service Executive, 2011), 
although only a small number had sufficient training to 
initiate methadone treatment in primary care settings. In 
2008, two thirds of methadone clients were treated in 
clinics and one third were treated in community-based 
settings (Health Service Executive).
From the mid-1990s, the rapid diffusion of heroin 
extended beyond the geographic boundaries of Dublin; 
however, methadone provision was very limited in these 
nonurban areas. Although the availability of MMT has 
expanded to some areas outside Dublin city, the waiting 
time for treatment is extensive in some locales. Surveillance 
and tracking of MMT clients are conducted through the 
Central Treatment List, which included 10,213 MMT cli-
ents in 2008 (European Monitoring Centre for Drugs and 
Drug Addiction, 2010). In both jurisdictions, methadone is 
dispensed largely through community-based pharmacies, 
and most MMT clients undergo some degree of supervised 
consumption. Fixed durations of MMT provision are not 
specified in either region.
Methods
In this article, we pool data from four studies that we 
conducted in one of two regions (Northern Ireland and the 
Republic of Ireland). Although our original studies did not 
focus exclusively on clients’ experiences with substitute 
prescribing, in each of the studies we interviewed indi-
viduals who were dependent on heroin, a proportion of 
whom had participated in a methadone maintenance pro-
gram. Two of the studies were conducted in Northern 
Ireland (Harris, 2011; McElrath & Jordan, 2005), and the 
remaining two were conducted in the Republic of Ireland 
(McElrath, 2008; 2009). We followed strict ethical proto-
col in each study, and ethical approval was granted by the 
Research Ethics Committee, School of Sociology, Social 
Policy and Social Work, Queen’s University, Belfast. 
Harris received additional ethical approval from the 
Research Ethics Committee, Northern Ireland, and was 
cosponsored by Queen’s University, Belfast and the 
Belfast Health Trust. Respondents who were interviewed 
by Harris provided written informed consent prior to data 
collection, and participants in the three other studies gave 
verbal informed consent. Respondents provided implicit 
consent for the interview data to be used in various arti-
cles. Direct and indirect identifiers that emerged during 
interviews were omitted during transcription. Digital and 
tape recordings were kept in secure storage in a university 
office. We transcribed interviews for the study with which 
we were affiliated, a strategy that reinforced confidential-
ity. Additionally, we protected typed transcripts through 
individual passwords. We did not have access to the full 
transcripts that were generated in the original studies in 
which we were not directly involved. We reimbursed all 
respondents for their time and travel expenses. We briefly 
describe the studies below, and provide sample character-
istics in Table 1.
Study A (heroin use and injecting drug use, Northern 
Ireland). Harris (2011) focused on risk environments and 
their influence on route of administering heroin, initiation 
and transitions to and from injecting, and patterns of her-
oin use among 54 adult men and women who had used 
Table 1. Sample Characteristics of the Four Studies
Study N Heroin MMTa
Average 
Age Women
Heroin/IDU-NIb 54 100% 44% 32 33%
IDU-NI 90  97% 24% 31 30%
Problem Drug 
Use-ROIc
35  80% 36% 28 46%
Drug Misuse-ROI 36  39% 64% 25 29%
aPercentage maintained on methadone among individuals dependent 
on heroin
bInjecting drug use, Northern Ireland
cRepublic of Ireland
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heroin within the 4-week period prior to the interview. 
Data were collected between 2008 and 2010. A total of 
44% of study participants were maintained on methadone 
at the time of the interview.
Study B (injecting drug use, Northern Ireland). McElrath 
and Jordan (2005) examined patterns of injecting, risk 
behaviors associated with injecting drug use, and experi-
ences with drug services where relevant. The authors col-
lected data over a 10-month period, ending in September 
2004. In total, 90 adult men and women were interviewed 
by McElrath or by a privileged access interviewer. A total 
of 40% of the respondents were in contact with some 
treatment service at the time of the interview.
Study C (problem drug use, Republic of Ireland). 
McElrath (2009) explored drug service needs and expe-
riences with drug treatment among adults experiencing 
problems with drug misuse—namely heroin, cocaine, 
and/or benzodiazepine. The study site was North 
County Dublin, and data were collected in 2008 and 
2009. McElrath interviewed 10 individuals who were 
on methadone maintenance at the time of the study, and 
25 individuals who were regular users of heroin, 
cocaine, and/or benzodiazepines and were not in con-
tact with treatment services.
Study D (drug misuse, Republic of Ireland). McElrath 
(2008) analyzed people’s experiences with drug treat-
ment and related services, and identified gaps in service 
delivery. The study site was a large town on the east coast 
of Ireland and outside the Dublin metropolitan area; data 
were collected in 2008. McElrath interviewed 36 adult 
men and women, of whom 39% had used heroin (primar-
ily through smoking), and 25% had current or previous 
experience with methadone maintenance in the area.
Our choice of the four study sites was based on two 
reasons. First, although we were principal investigators 
(PI) for the studies, we did not hold joint responsibility 
for any one study. As PIs, we conducted and transcribed 
interviews and analyzed the data; thus, we knew the data 
well. Second, we discussed and shared emerging findings 
over the previous several years, and we began to observe 
several similarities across the study sites in terms of how 
people experienced methadone maintenance.
Analytical Approach
The methodological strategy of pooling qualitative data 
from multiple studies has several advantages. For exam-
ple, the approach makes efficient use of data, allows for 
checks on construct validity across research settings and 
time periods, and reflects a degree of triangulation 
(Hammersley & Atkinson, 1995). Our strategy evolved 
over a 3-year period, commencing with our discussions 
of the social worlds of people who use heroin. We were 
involved in separate studies but often shared preliminary 
research findings pertaining to the experiences of respon-
dents, including their stories about treatment services. As 
we shared and processed these experiences, we noted that 
respondents’ social worlds were often shaped by inten-
sive surveillance consistent with a social control frame-
work. We began with a broad notion of social control and 
borrowed from the work of Cohen (1985) and his 
descriptions of surveillance of the deviant in a panoptic 
world. We remained open to other interpretations after 
several reads of the interview transcripts, noting themes 
and comparing data across these themes.
We identified emerging themes that pertained to dif-
ferent settings of MMT provision, interactions between 
MMT clients and service providers, and other experi-
ences of MMT clients within the context of service deliv-
ery. The concept of institutionalized stigma surfaced in 
clients’ stories about their experiences. We defined and 
examined outliers or deviant cases, and explored the con-
ditions under which outliers might be explained. In gen-
eral, the analytical approach involved largely inductive 
but also deductive reasoning.
A limitation of the analysis concerns the use of second-
ary data. None of the original studies focused specifically 
on experiences with methadone maintenance. This point 
raises the issue of data saturation. The sample sizes in the 
original studies were determined by funding agencies, 
although data saturation with regard to the original concepts 
was reached before final interviews were completed in 
those studies. Some of the themes we discuss in the present 
article emerged relatively quickly in the four original stud-
ies. However, had the original studies focused specifically 
on experiences with MMT, we would have likely recruited 
larger numbers of MMT clients to ensure that saturation 
relating to methadone experiences had been reached.
Results
Addict Identity as Master Status
Individuals who held power over methadone provision 
often framed client identities around the master status of 
“addict.” Furthermore, MMT clients were treated as 
addicts regardless of their stage of recovery. The saliency 
of this identity was manifested through (a) rules and 
regulations that equated addicts with deviants and crimi-
nals, (b) contractual power differentials, (c) labels that 
incorporated a clean/dirty dichotomy, and (d) clients’ 
lack of input into treatment decisions.
The addict as criminal. Stereotypical views about heroin 
addicts were closely tied to assumptions of deviance and 
crime. The majority of MMT clients in both jurisdictions 
visited on a daily basis pharmacies where methadone 
consumption was supervised by the pharmacy staff. 
Within these settings, clients from both jurisdictions were 
aware that they were watched closely and assumed to be 
deviant:
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One time I was buying toothpaste—toothpaste, 
like. She [counter staff] thought I was trying to 
steal it. Why would I steal toothpaste? And if 
somebody was stealing toothpaste, why would they 
steal it from the chemist where they get their 
methadone? I know it’s hard on the chemist too. 
Maybe they get ripped off [robbed] sometimes. But 
see being treated like that? Everyone needs to go 
through that to see what it’s like.
They would literally watch you and follow you to 
the door, like you’ve just been caught shoplifting. 
That’s how you would feel, which I think is just 
damn right rude. Now they’ve been told and told 
and told from [consultant psychiatrist], apparently, 
to stop.
Alleged fears that MMT clients would engage in 
shoplifting were reflected in rules and regulations that 
were imposed on clients in selected pharmacies. These 
additional regulations were particularly evident in the 
Republic of Ireland, where MMT clients from the two 
study sites reported that they were not permitted to enter 
the dispensing pharmacy with friends or adult relatives. A 
few MMT clients perceived that pharmacy staff assumed 
that clients’ social networks were comprised only of other 
addicts, and that shoplifting could be curtailed by prohib-
iting groups of addicts in the pharmacy at any one time. 
These experiences were described by MMT clients in the 
South of Ireland:
Loads of pharmacists in town told meth [metha-
done] clients that they can’t bring friends [with 
them into the pharmacy]. You can’t bring friends 
unless they are buying something. What about 
other people picking up prescriptions for drugs? 
How come they bring friends?
The policy created difficulties when two or more cli-
ents happened to arrive at a pharmacy at the same time:
You see, we sign this contract, and we’re not sup-
posed to go in with other people. One time in 
[town], there were four of us who got there 
together. He [the pharmacist] said to me, “You’re 
last in, you go out [and wait until the others have 
left the pharmacy].” I had my baby with me and 
it was raining, and then there was loads of us 
standing outside in the rain, and me with the 
baby. Now he [pharmacist] did apologize when 
he saw the baby.
It doesn’t take a genius to know why you’re in 
there. You had to sit in a chair. She had to call my 
name before I could go to the counter. You’d swear 
I had leprosy. And you couldn’t go in if someone 
else was in there getting their methadone. There 
was like a screen, and you could see the top of their 
head [someone else taking the methadone]. I’d wait 
outside ’til they finished.
Contractual power differentials. The continuation of 
MMT depended in part on how clients behaved. Some cli-
ents in the South were provided with a contract, but were 
not asked to sign them. The contracts listed various client 
behaviors that could result in penalties. Clients in the 
North were required to be punctual for appointments with 
key workers and prescribing doctors, and a 24-hour notice 
was required to change the time or date of appointments. 
Although the contract was signed by the client, the pre-
scriber, the dispenser, and the key worker, the behaviors 
outlined in these contracts related to the client only. Our 
review of the contractual language suggests an emphasis 
on controlling client behavior through rules that reinforce 
addict and deviant identities. Clients in the North faced 
“possible discharge” or the withholding of methadone for 
“consistent tardiness,” for missing two consecutive 
appointments, and for “inappropriate” behavior in phar-
macies. Clients in the South reported similar rules that 
regulated clients’ behavior in these settings:
Respondent (R): I think they [pharmacy staff] just 
need to treat people better from the start. They 
look at us like dogs, [as if we are] robbing and 
all. You see that paper [list of rules; contract] 
they give us when we start? We’re not supposed 
to even look around the room.
Interviewer (I): What room? The whole pharmacy?
R: Yeah, we’re just supposed to look straight ahead, 
not look around at all. And we have to sit there.
“Clean/dirty” dichotomy. Speech associated with heroin 
dependency includes references to “clean” and “dirty,” 
and these words equate with good and bad behavior.1 
Individuals are “clean” when in recovery, or when they 
have abstained from using heroin even for a brief time. 
MMT clients who are clean are often rewarded by treat-
ment services. For example, they might be entitled to 
reduced visits to the clinic, and might be granted unsu-
pervised methadone consumption in the form of take-
home doses. The “unclean” clients undergo more regular 
surveillance in the form of supervised consumption, 
daily collections of methadone, frequent meetings with 
drug workers, and the dreaded urinalysis testing for psy-
choactive substances other than methadone. If former 
addicts are clean, then by comparison, addicts are 
“unclean” or “less clean.” This dichotomy and the asso-
ciated system of reward and punishment serve to rein-
force the distinction between good and bad behavior, and 
amplify the addict identity.
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The tool of urinalysis is justified as a means to deter-
mine treatment compliance and to prevent overdose. The 
results of urinalysis are also dichotomized, whereby 
urines are either clean (no evidence of recent use of psy-
choactive substances) or dirty (recent consumption of 
psychoactive substances other than methadone), and dirty 
often reflects use of heroin. The psychoactive effects of 
methadone and its associated dependence are deemed by 
service providers to be acceptable in the name of treat-
ment. Methadone clients are clean, whereas heroin use is 
considered to be dirty. Yet the effects of methadone have 
the potential to socially and physically incapacitate MMT 
clients (Bourgois, 2000). Nevertheless, consistent “clean-
liness” is likely to be rewarded (although not praised), 
whereas clients who provide “dirty” urines are subjected 
to warnings, reprimands, and sometimes punishment.
Prior to 2008, MMT clients in the North were subjected 
to program dismissal when three consistent urine samples 
showed dirty results. A change in policy in 2008 meant that 
clients who consistently (e.g., three times) provided dirty 
urines are referred to an “enhanced clinic” where they no 
longer have contact with their key worker; rather, use of 
heroin and other nonprescribed substances is monitored by 
a consultant psychiatrist. Similar procedures were in place 
in one study site in the South of Ireland, where one partici-
pant noted, “Stablized people go on Wednesday. That’s me. 
One dirty urine, and they could put me back to Thursday.” 
The dirty are separated from the clean, and this segregation 
is justified in terms of preventing the dirty from influenc-
ing the clean. The dirty are believed to have the power to 
influence the relapse of the clean.
As a mechanism of social control, urinalysis repre-
sents a powerful and intrusive form of surveillance. 
Clients in both jurisdictions reported procedures whereby 
urine samples were required under the watchful scrutiny 
of staff. Collecting and handling urine samples were 
heavily regulated under the assumption that addicts are 
deviant. For example, procedures were in place to deter 
clients from substituting their own urine with another’s 
clean urine, or to prevent urine dilution with toilet water. 
Surveillance of urine sample provision differed across 
services located in the North. In particular, the regula-
tions of one clinic were described as punitive:
[Addiction service] is far better. Just the way they 
get on [do things; provide the service]. They’re not 
all having a go at you ’cause you’re giving dirty 
samples and all. They don’t stand over you and 
watch you go to the toilet like in [other addiction 
service]. They let you go in privacy and stuff like.
Recovery from drug dependence is a process. 
However, as a means of social control, the clean/dirty dis-
tinction served to dichotomize recovery and reinforced 
spoiled identities. In turn, the dichotomy restricted oppor-
tunities for developing client identities that incorporated 
incremental steps of the self in recovery.
Lack of input in treatment decisions. MMT clients in all 
four studies recalled feelings of powerlessness over treat-
ment decisions that were determined by service providers. 
Some of these decisions were based around methadone dos-
age, although we found only limited evidence of inadequate 
dosages. The majority of MMT clients from Study A 
reported satisfaction with their methadone dosage at the 
time of interview. However, some respondents recalled dif-
ficulties in negotiating a suitable level of dosage, i.e., a level 
that would “hold” them, diminish cravings and the effects 
of withdrawal. Northern clients raised concerns about the 
power of addiction services to define the amount of metha-
done needed for stabilization. Clients resisted the uniform 
dosage policy—the “one size, fits all” approach after sev-
eral months or years on MMT. Indeed, one respondent (the 
only study participant who had initiated an extant com-
plaints procedure) had been very proactive in challenging 
the dominant discourse relating to suitable methadone dos-
ages. He reported that his current dosage exceeded 150mg:
They [addiction service] were saying that 120[mg] 
was the limit and that they weren’t gonna put me 
up any higher. Eventually I ended up putting in a 
complaint to the Health Board, and eventually I got 
a test done on how the methadone was metabolized 
by my blood plasma. I researched it myself and 
found that there’s cases where some people—their 
metabolism can affect the methadone. They metab-
olize it at different rates. But then I actually got 
moved up [dosage increased] . . . it more or less 
takes me through until about 8.00 in the morning, 
and then I feel a bit rough for about an hour, which 
is an awful lot better compared to what I was.
In Study D (Republic of Ireland), some respondents 
perceived their current methadone dosage to be too low. 
A woman respondent indicated that her current daily dos-
age of methadone (i.e., 50mg) was insufficient, and had 
reported this problem to addiction services on several 
occasions. At the time of interview, her dosage level still 
had not been increased. As a result, she was “topping up” 
with heroin periodically to avoid withdrawal and crav-
ings. In the same locale, adjustments to dosage levels and 
withholding methadone altogether were at times used as 
punishment: “I was three minutes late one time—three 
minutes, and they took me down five mg [decreased the 
methadone dosage level].” Another client reported, 
“Some chemists in town—if you’re late, they’ll pour 
methadone down the sink. Pour it down, I swear. There’s 
you—using heroin again.” Dosage penalties were also 
recalled by MMT clients in the North:
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When they see people who are still using heroin 
and using their methadone it’s not just because they 
want to get extra stoned [intoxicated]. Maybe 
there’s an underlying reason why . . . the methadone 
isn’t holding them enough so they need extra 
doses. With [addiction service], if you’re caught 
using [heroin], it seems to be that you’re given a 
warning, and then given another warning, and then 
you’re struck off [forced to leave treatment]. I’ve 
heard cases of that happening. One thing that I’ll 
say for [consultant psychiatrist] is that he was 
always fair. If you were using he wouldn’t condone 
it, but he would think that it was better maybe 
using once or twice and being on the methadone, 
once or twice in a week, as opposed to maybe using 
once or twice a day every day, so harm reduction.
In these instances, dosage penalties (and threats of 
dosage penalties) were perceived as mechanisms of social 
control that were used to encourage clients to conform to 
the rules of the clinic and pharmacy. Although proper 
dosing is important for preventing overdose, insufficient 
dose levels can contribute to relapse into heroin use.
The lack of client input in treatment decisions also 
was revealed through clients’ concerns over progress. 
In the Republic of Ireland, clients’ preferences for 
reducing methadone dosage levels over time did not 
appear to be an option at the two study sites (Study C 
and Study D). Two men from Study D were interested 
in having their methadone dosage level reduced gradu-
ally, in hopes of eventually coming off methadone com-
pletely. One client reported being depressed because he 
believed that his goal was ignored by addiction ser-
vices: “I’m afraid of methadone. The years are flying 
by and I’m still on it. They won’t let me come down 
[reduce dosage].”
Similar concerns were voiced by respondents in Study 
C. Despite abstaining from injecting drug use for several 
years, MMT clients were unable to see the progress they 
had made because they saw themselves as still being opi-
oid dependent. They reported that gradual detoxification 
from methadone was rarely mentioned as an option for 
them: “Do you know anybody who’s been on methadone 
for a few years? Got off the methadone and not on heroin 
again? People can’t get off methadone, and if they do it’s 
right back to the heroin.” Other clients voiced similar 
concerns: “I think of all the people who have used heroin. 
Loads of them, and I only know a few people who got off 
it. I know people who’ve been on methadone for years. 
That scares me.”
Some respondents in the North voiced their concerns 
over what they perceived to be a blanket policy to retain 
people on methadone with no option of reducing. One 
respondent reported,
Methadone’s a cure but methadone isn’t a long-
term cure. Methadone is there to cure you in the 
short term, but they’re doing it wrong here. They’re 
putting people on methadone for years and years 
and years . . . . If you go and say to them, “Could 
you put my methadone up?” they say to you, “You 
don’t need it to go up.” But see if you go in and say 
to them, “Could you start to take me down off my 
methadone?” they turn around and tell you that you 
need to go up. But if you go in and say that you 
need to go up they’ll say you don’t . . . . [Addiction 
service] is a load of shit, to be honest with you.
Over time, a few respondents were able to negotiate 
low dosages of methadone, which they believed kept 
the withdrawal symptoms and cravings at bay. These 
individuals envisioned a time when they would not be 
using heroin or methadone. Although methadone pre-
vented withdrawal symptoms, they feared long-term 
use of the treatment more than heroin itself (see 
Bourgois, 2000). Overall, treatment was determined 
largely if not solely by addiction staff, with limited 
input from clients. For the most part, MMT clients were 
passive recipients of treatment, and this provision rein-
forced power imbalances between service providers 
and clients. We suggest that encouraging client passiv-
ity in treatment serves to reduce the likelihood of self-
empowerment in recovery.
Undeserving Customers
Several clients perceived that they were treated as unde-
serving customers in pharmacies and clinics. This theme 
was reflected by (a) limited privacy and lengthy wait 
times, and (b) poor facilities.
Limited privacy in pharmacy settings. In the context of 
methadone provision, pharmacy settings are important 
because MMT clients come into contact with “normals” 
(Goffman, 1963) within these venues (Lloyd, 2010); thus, 
addict identities become visible to the public gaze. Cli-
ents’ perceptions of the gaze were heightened because 
they were placed well down the list of preferred phar-
macy customers. The public wait was described as 
“embarrassing” or “agonizing”:
Sometimes I have to wait half an hour to get my 
meth. She has to serve everyone first, even people 
who come in after me. I’m waiting there, and peo-
ple looking at me like I’ve got two heads. She’s 
getting paid for helping us, but you feel like you 
have to kiss her toes.
In the present study, space restrictions within pharma-
cies might have been one factor that contributed to 
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settings that were devoid of privacy. For instance, some 
MMT clients reported regular consumption of methadone 
behind temporary screens that had been set up for that 
purpose. A few others reported that consumption occurred 
within photo booths that were located inside pharmacies. 
For other respondents, however, methadone was con-
sumed in the presence of other customers. In both the 
North and South of Ireland, lack of privacy was of great 
concern to clients because they perceived this setting to 
be characterized by a stigmatizing public gaze:
You can ask to go in there [separate and private 
room], but you have to make a point of it. I ask [for 
privacy], as there’s members of my old work and 
others [present] . . . there’s always people standing 
there, and I get really embarrassed.
Private? It’s not really that private. They walk out 
with the cup [of methadone] like. And plenty of 
time there’s some people in there—especially at 
lunch hour. Walks out with the cup, and says, 
“C’mon [client].” And I go into the room—not 
really a room; that’s where they take the photos. 
And everyone knows what’s in the cup.
Very few clients complained directly to the pharma-
cist or other service provider about the difficulties they 
(clients) had experienced in the pharmacy setting. 
MMT clients lacked a voice (“Who’d believe a 
junkie?”), and often feared that methadone provision 
would be discontinued if they voiced complaints. This 
perceived threat was enough to encourage clients to 
“keep their heads down,” mind their manners, and 
avoid “rocking the boat.”
Several clients attempted to minimize the stigma 
associated with the public gaze of the addict. For exam-
ple, some arranged for early morning visits to pharma-
cies, when fewer customers were present. Other clients 
reported waiting outside the pharmacy until other cus-
tomers had left, or had occasionally purchased a phar-
macy item so as to appear like “normal” customers 
while waiting for others to be served. MMT clients 
residing in small towns, villages, or particular housing 
estates appeared to be more affected by the local public 
gaze. This finding pertained to MMT clients in both 
jurisdictions:
I would be nervous going in there. There’s a few 
reasons. Your ordinary people come and get their 
prescriptions. Could be your mom’s mate, someone 
down the lane, someone in the UDA [Ulster 
Defence Association, a loyalist paramilitary group 
in the North of Ireland].
It might be packed with people. Maybe your next-
door neighbor. You got to get a cup of water and 
your methadone, and drink it. There’s a wee [small] 
private area, but people [other customers] know 
what’s going on back there.
To some extent, Belfast respondents voiced less con-
cern about the public gaze in pharmacies. The urban 
environment might have provided the perception of ano-
nymity within the Belfast pharmacies. Some clients 
negotiated a change to another pharmacy, in hopes of 
minimizing this stigma. A change in pharmacy was often 
beneficial for clients, and finding the right pharmacist 
appeared to increase clients’ self-esteem on the slow 
road to recovery:
Gentleman like [pharmacist]. He’s stood by me, 
looked after me when I was down in the dumps and 
all. Gives you time, know what I mean? He would 
talk to you and you can go round the shop with 
him. “Have you twenty minutes?” [And he says] “I 
have, aye.” I mean, we’ve talked so much and  
he knows when there’s something wrong with me 
like . . . . So if there is anything wrong I would go 
and talk away to him.
Poor facilities. The physical appearance of clinics dif-
fered across the two regions. In particular, our observa-
tions of some clinics in the South of Ireland showed very 
grim, depressing, and near-dilapidated external facades 
that were characterized by barbwire and high barricaded 
walls, surrounded by litter-strewn entrances. In the North, 
the majority of facilities appeared similar to doctors’ 
offices and other “respectable” health centers. At the time 
of the studies, the interior design of most northern clinics 
suggested a somewhat welcome atmosphere, with orga-
nized reading material available in waiting rooms, simple 
but fairly new décor, and the appearance of cleanliness. 
In contrast, the two southern study sites were character-
ized as being more “clinical” and less welcoming in 
appearance. In one southern site, toilet facilities were 
described by MMT clients as particularly demeaning. 
One respondent reported, “There’s one toilet and there’s 
urine all around the toilet bowl. It’s disgusting.” A woman 
client had accessed addiction services at the same site:
I hate going to the toilet there. There’s urine every-
where, and can you get something from someone 
else’s piss? Can you get AIDS? I try and clean up 
the urine before I go, and then I wash my hands 
like mad.
MMT clients in this locale perceived that treatment 
staff thought them undeserving of clean toilets. Rather, 
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the assumption was that “dirty” toilets are appropriate for 
“dirty” people. None of the respondents in Study D had 
ever complained to treatment staff about the condition of 
the restrooms. MMT clients were voiceless under the 
powerful constraints of treatment and those who held 
power over it.
Barriers to Reintegration 
If one objective of drug treatment is to encourage and 
perhaps facilitate reintegration into mainstream society, 
then clearly, participating in meaningful employment is 
part of this process. However, the conditions under which 
MMT is provided can act as barriers to finding suitable 
employment and staying employed. Some respondents in 
Study D were searching for meaningful work, yet were 
conscious of the need to collect methadone frequently, 
and perceived that this lifestyle routine could affect rela-
tionships with employers. In this locale, seeking employ-
ment was deferred for another day. A man participant 
from the North reported similar difficulties:
It’s too much hassle. I got a phone call, says would 
I like to have a job. I was interested. It started at 
8.00 in the morning and finished around 5.30. How 
could I get the [methadone] script [prescription]? I 
needed to be in town at 9.00 or 9.30 [pharmacy 
opening hours], or else be back by 4.30 or 5.00 
[closing hours]. I need to find work that allows me 
to get my script.
Although some MMT clients in the North (Study A) 
reported that they had worked while being dependent on 
heroin, none were searching for work at the time of inter-
view. We attributed this finding to the regulations and 
routines of MMT:
I was working when I was on the heroin, when I 
had a pretty big habit. I was able to hold a job—no 
problem—whereas on the methadone at the min-
ute, there’s no way that I feel like I could hold 
down a job. I’m waking up in the morning feeling 
rough. Three days a week I have supervised con-
sumption. Four days a week I have it [methadone 
doses] home with me. So there’s not gonna be very 
many employers who go, “That’s okay. Sure, come 
in an hour or two after you get your methadone,” 
you know?
In one of the four study sites (Study C), nearly all of 
the MMT clients who participated in an interview worked 
in part- or full-time employment, consistent with county-
wide data claiming the highest rate of labor force partici-
pation in 2006 (Central Statistics Office, 2006). MMT 
clients in that study noted the difficulty associated with 
collecting methadone during working hours. A man 
reported,
The woman [counter staff] there looks down on 
you—all the time. Well, she’s not there all the time. 
But when I see her, I go, “Oh God—here it comes.” 
I was working, every day. See that chemist? It’s 
always packed. I had [a] half hour for my lunch 
break, and it would take me half an hour to get my 
methadone . . . loads of times she’d keep me wait-
ing ’til everyone had gone. And me getting back to 
work late. You’d have to sit there ‘til everyone was 
away. Then they’d get your methadone. I’d be late 
for work after lunch, like. And they [coworkers] 
don’t know I’m taking methadone.
Some respondents in Study C disclosed their MMT 
involvement to their employers or a trusted coworker. 
Others tended to carefully guard their treatment partici-
pation for fear of losing their jobs or being treated differ-
ently at work. Strategies to avoid potential stigma were 
incorporated into daily lifestyles. Indeed, some respon-
dents described how they saw but never took possession 
of the business card that contained information about the 
study, used in an effort to recruit participants. They 
voiced apprehension that their drug use history might be 
disclosed if another party observed the card in their pos-
session. A woman respondent and MMT client worked in 
a financial institution at the time of interview. Distancing 
herself from a drug user identity was paramount to her 
self-image and how she perceived others might view her: 
“I got the card, but I couldn’t carry it with me. Thought 
maybe work might find out. Didn’t want to leave the 
card at work.”
A respondent in Study C had held the same job for 
several years, but had never disclosed his MMT involve-
ment to his employer. He had long ago negotiated take-
home methadone doses so that his work routine would 
not be affected. The respondent attributed meaningful 
employment to his involvement in MMT: “I’ve been with 
them for eight years, and it’s the longest time that I’ve 
had a job. And that’s due to the methadone.”
Discussion
Methadone provision in both jurisdictions was charac-
terized by social control and institutional stigma, which 
served to reinforce spoiled identities, expose “unde-
serving customers” to the public gaze, and create barri-
ers to reintegration. We observed more similarities than 
differences across the study sites, but noted the con-
trasts in terms of the physical structure of the clinics 
(facilities in the North were more likely to resemble 
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mainstream health centers) and pharmacy regulations 
that prevented MMT clients being accompanied by 
friends during pharmacy visits (southern sites). We con-
clude that social control is multifaceted and layered 
within and across the contexts in which MMT is pro-
vided. The layers of social control derive from the offi-
cial registers or lists of MMT clients. In the official 
quest to identify and track MMT clients, informed and 
voluntary consent to be part of these lists is deemed to 
be unnecessary. The layers of social control expand 
from the official registers to the settings of clinics and 
pharmacies, and extend further to regulations and sur-
veillance within these settings. In the clinics, for exam-
ple, social control features in drug testing through 
urinalysis, dosage decisions, clean/dirty distinctions, 
and sanctions over missed appointments. Layers of 
social control within pharmacies are reflected in the 
wait experienced by “undeserving customers,” the 
watchful gaze of pharmacy staff, and the rules that gov-
ern client behavior (e.g., contractual obligations).
These layers of social control are tied closely with 
institutional stigma. The label of addict emerged as a 
salient identity among MMT clients, and was imposed by 
service providers. Moreover, addicts were interpreted to 
be untrustworthy and part of a “dangerous class.” Opsal 
(2011) described the social control of parolees with 
“felon” identities. Respondents in her study “lived under 
a system of surveillance that bounded their behavior” 
(p. 142). She noted for example, the practices of regular 
drug testing, frequent meetings with agents of social con-
trol (i.e., parole officers), rules that prevented association 
with other felons, and the power over the body (i.e., 
parole officers had discretion over recommendations for 
parole revocation). These methods of regulating felon 
behavior are strikingly similar to the experiences of MMT 
clients in the present study, where spoiled identities 
equated addicts with criminals. Frequent exposure to 
institutional stigma across various settings served to rein-
force spoiled identities of MMT clients.
MMT is most often utilized among people presenting 
with heroin dependence, and heroin is often viewed as the 
least-acceptable drug, even among individuals who are 
“heavy” users of other illicit drugs (McElrath & McEvoy, 
2001). In a previous study, Radcliffe and Stevens (2008) 
found that individuals whose addiction was associated 
with drugs other than heroin dropped out of treatment in 
an attempt to disassociate themselves from “junkies.” 
Similar to people’s assumptions about HIV (Miles, Isler, 
Banks, Sengupta, & Corbie-Smith, 2011; Worthington & 
Myers, 2003), heroin dependence is perceived to be 
linked to lifestyle rituals that are associated with devi-
ance, e.g., injecting drug use (Simmonds & Coomber, 
2009), and conditions that are presumed to be dangerous, 
e.g., blood-borne viruses. Moreover, heroin dependence 
is perceived to be intertwined with criminal activity 
(Radcliffe & Stevens); hence, MMT provision is situated 
between the ideologies of medicalization and criminal-
ization (Vigilant, 2004).
We recognize that various drug treatment modalities 
can be stigmatizing (Luoma et al., 2007), but we suggest 
that in comparison to other interventions, MMT is char-
acterized more by social control and institutional stigma 
that reinforce and perhaps create spoiled identities. We 
believe that this difference has its roots in how heroin 
dependence is perceived and stereotyped, and how these 
perceptions are connected to individuals who experience 
heroin dependence. Moreover, clients involved with other 
types of drug treatment are generally not exposed to the 
public gaze in pharmacies. Still, it would be useful to 
compare social control mechanisms across a diverse 
range of modalities that are designed to treat individuals 
with heroin dependence.
Perceptions about MMT clients are in some ways 
consistent with statutory MMT protocols (e.g., drug 
testing, supervised consumption of methadone, con-
tracts) that permit and sometimes require some of the 
rules and regulations that characterized provision in 
these jurisdictions. Institutional stigma is reflected in 
some of these protocols; thus, “stigma plays a key role 
in producing and reproducing relations of power 
and control” (Parker & Aggleton, 2003, p. 16). The 
implication of these findings is that institutional stigma 
has the potential to discredit and negate self-recovery, 
particularly when individuals internalize the stigma. 
(Re)developing nonaddict identities is important for 
recovery (Biernacki, 1986), and positive self-identities 
are likely to surface in the absence of institutionalized 
and internalized stigma. Institutionalized stigma disem-
powers MMT clients, whereas recovery requires 
empowerment. Internalized stigma can contribute to 
leaving treatment prematurely (Lloyd, 2010), which has 
been linked to increased likelihood of mortality 
(Fugelstad et al., 2007; Magura & Rosenblum, 2001). 
Moreover, when individuals are devalued by the treat-
ment process itself, how can recovery be achieved?
MMT might be the most regulated and controlled 
intervention that operates under the guise of treatment. 
By comparison, Fischer et al. (2005) noted that patients 
being treated for diabetes and AIDS are not “penalized by 
the treatment provider for not complying with the pre-
scribed treatment” (p. 3). We compare the social control 
of MMT with long-term use of benzodiazepine, pre-
scribed by physicians. Benzodiazepine dependence is 
well-documented in Ireland. Intended for short-term 
relief for anxiety, repeat prescriptions in the country have 
been described as commonplace (Department of Health 
and Children, 2002). However, patients in receipt of 
repeat prescriptions do not consume the medication in the 
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presence of specialist providers, and are not required to 
submit to urinalysis testing. These controls are not in 
place, despite benzodiazepines being implicated in over-
doses when combined with alcohol (Koski, Ojanperä, & 
Vuori, 2002; Tanaka, 2002), and being diverted to illicit 
markets (Fountain, Griffiths, Farrell, Gossop, & Strang, 
1996; Inciardi, Surratt, Cicero, & Beard, 2009). This con-
tradiction in pharmacological delivery must be explained 
by the spoiled identities of heroin “addicts” who remain, 
even after several years, on MMT.
Under the current service provision in North and 
South Ireland, methadone maintenance is best viewed as 
an intervention rather than a treatment modality. The 
pharmacological potential of methadone is undermined 
by clients’ experiences of MMT provision, which is 
inconsistent with contemporary visions of treatment and 
harm reduction. MMT provision is characterized by 
highly regulated social control mechanisms and institu-
tional stigma that (a) reduce the likelihood of developing 
trusting relationships between providers and clients, (b) 
reinforce spoiled identities of clients, and (c) view cli-
ents as passive recipients of treatment. Unlike individu-
als who seek other health provision, MMT clients are not 
treated as patients (Vigilant, 2001), but as suspects. 
MMT is more about controlling behavior than treating 
disease (Bourgois, 2000; Saris, 2008), and the control of 
clients’ behavior is justified because of stereotypical 
assumptions that addicts are a deviant and to some extent 
dangerous class.
Suggestions for Change
We suggest that social control and institutional stigma 
create the conditions for poor outcomes with MMT. So 
how can stigma-free MMT be provided in the context of 
multifaceted social control? First, there is an urgent 
need to reframe MMT provision so that clients are 
viewed as customers (Fraser & Valentine, 2008) or con-
sumers (Reisinger et al., 2009) in the various contexts 
of service delivery. This ideological change represents 
an important step for reducing social control and insti-
tutional stigma. In regions where service users are not 
organized collectively, MMT programs can develop 
autonomous groups of service users and commit to dia-
logue for resolving complaints. Patterson, Backmund, 
Hirsch, and Yim (2007) argued that interventions 
designed to reduce stigma must consider macro-level 
changes. They offered the example of hospital advisory 
groups consisting of service users who could contribute 
to the development of antistigma interventions. They 
also suggested that advisory members should be com-
pensated for their work. Broadening the voice of MMT 
clients to directly influence MMT programs has the 
potential for improving service delivery, boost retention, 
and benefit recovery. Although the Irish and British 
governments have recently called for service user 
involvement in the provision of health care, it remains 
to be seen whether the voice of the service user will 
have substantive impact.
Second, although relocating drug treatment services 
to mainstream health centers might reduce the stigma of 
treatment (Radcliffe & Stevens, 2008), some general 
practitioners have voiced resistance about treating 
patients with drug problems (Matheson, Pitcairn, Bond, 
van Teijlingen, & Ryan, 2003), which could result in the 
displacement of institutional stigma from clinics to phy-
sicians’ offices. Instead, White (2010, p. 46) recom-
mended that MMT clinics alter their “institutional 
identities” and be referred to as “addiction recovery 
centers” that are reflected by “strong cultures of recov-
ery.” Service users should be encouraged to develop a 
stake in ownership by participating in meaningful pro-
gram aspects. These centers should actively involve 
individuals who were once heroin dependent but have 
since gained employment, education, training, or other 
meaningful life change. It is important that MMT clients 
know and learn from empowered others who also have 
experienced heroin dependence. Additionally, “clean” 
and “dirty” discourses should be avoided, and replaced 
with language that does not demonize or create hierar-
chies of MMT clients.
Third, there is an urgent need to rectify the institu-
tional stigma that occurs in pharmacies. This issue rep-
resents significant challenges, because methadone is 
often dispensed in private pharmacies that lie outside 
the gaze of auditing. We suggest that antistigma training 
be required of pharmacists and counter staff, and that 
regular feedback meetings be held between pharmacists 
and collective groups of service users. Finally, we do 
not necessarily oppose the use of contracts, but believe 
that contracts should be balanced and power differen-
tials eliminated by including specific responsibilities for 
prescribers, dispensers, treatment staff, and customers. 
Contracts should include the importance of privacy and 
confidentiality, and how these issues will be protected. 
Feedback from clients should be collected on a regular 
basis, and without threats to methadone availability or 
provision.
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